Quantification of pravastatin in human plasma and urine after solid phase extraction using high performance liquid chromatography with ultraviolet detection.
A high performance liquid chromatography (HPLC) method for the estimation of pravastatin in human plasma and urine samples has been developed. The preparation of the samples was performed by automated solid phase extraction using clonazepam as internal standard. The compounds were separated by isocratic reversed-phase HPLC (C(18)) and detected at 239 nm. The method was linear up to concentrations of 200 ng/ml in plasma and 2000 ng/ml in urine. The intra-assay variability for pravastatin in plasma ranged from 0.9% to 3.5% and from 2.5% to 5.3% in urine. The inter-assay variability ranged from 9.1% to 10.2% in plasma and from 3.9% to 7.5% in urine. The validated limits of quantification were 1.9 ng/ml for plasma and 125 ng/ml for urine estimation. These method characteristics allowed the determination of the pharmacokinetic parameters of pravastatin after administration of therapeutic doses.
Bauer
Steffen
S
Institute of Clinical Pharmacology, Charité-University Medicine Berlin, Campus Charité-Mitte, Schumannstr. 20/21, Berlin 10098, Germany. steffen.bauer@charite.de
Mwinyi
Jessica
J
Stoeckle
Angela
A
Gerloff
Thomas
T
Roots
Ivar
I
D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000097:blood* / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000652:urine*; D008297:Male; D017035:Pravastatin / Q000097:blood* / Q000302:isolation & purification / Q000493:pharmacokinetics / Q000652:urine*; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013056:Spectrophotometry, Ultraviolet
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D017035:Pravastatin